Sonia Lilia Mestizo-Gutiérrez

Prof. Dr. Sonia Lilia Mestizo-Gutiérrez

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
FRFausto Rojas-Durán
Fausto Rojas-Durán
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
LMLuis Roberto Tlapa Monge
Luis Roberto Tlapa Monge
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
Alzheimer’s disease (AD) is traditionally defined by Amyloid-β (Aβ) plaques and tau neurofibrillary tangles, yet these proteinopathies alone fail to explain disease heterogeneity, progression, and cognitive decline. Emerging evidence identifies chronic neuroinflammation as a central integrator that converts molecular pathology into synaptic failure and neurodegeneration. In this context, Aβ acts as a danger-associated molecular pattern that activates microglial and astrocytic immune programs through receptors such as TREM2, TLRs, and RAGE, leading to inflammasome activation, cytokine release, and oxidative stress. These responses pathologically re-engage developmental complement pathways (C1q–C3–CR3), driving excessive synaptic pruning that correlates more closely with cognitive impairment than neuronal loss. Reactive astrocytes further amplify dysfunction by impairing glutamate and potassium homeostasis, promoting excitotoxic and metabolic stress, while inflammatory glia facilitate prion-like tau propagation via extracellular vesicles. Concurrent neurovascular inflammation disrupts blood–brain barrier integrity and cerebral perfusion, reinforcing immune-metabolic failure. Importantly, neuroinflammatory biomarkers (GFAP, sTREM2, YKL-40, cytokines, complement, and TSPO-PET) provide dynamic readouts of disease activity and therapeutic response. Together, these findings position AD as a disorder of failed immune resolution and support precision immunomodulatory and pro-resolving therapies aimed at restoring neuroimmune homeostasis rather than merely removing protein aggregates.

29 June 2020 in Turkish Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
JMJorge Antonio Martínez-Díaz
Jorge Antonio Martínez-Díaz
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
FRFausto Rojas-Durán
Fausto Rojas-Durán
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
Luis I. GarcíaLuis I. García
Luis I. García
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
Objectives: Alzheimer’s disease is complex and involves several proteins. Most affected are Tau protein and amyloid precursor protein (APP) which, when cleaved by the enzymes β-secretase (BACE1) and γ -secretase (Nicastrin), yield the amyloid peptide. Although these processes take place mainly in neurons, it is not exclusive of them, as glia cells also contribute to these processes. The objective of this study was to evaluate the effect of nimesulide, resveratrol and citalopram on C6 (glioma) cells when exposed to Lipopolysaccharide (LPS). Methods: Expression levels of the proteins APP, BACE1, COX-2, Nicastrin and Tau-p were evaluated by Western-blot and ELISA in C6 cells by effect of LPS, and the drugs citalopram, nimesulide and resveratrol. Results: It was found that LPS is able to hyperphosphorylate Tau in this cell model and the drugs decrease hyperphosphorylation. We also found that the drugs increase the expression of APP, decrease BACE1 and promote the expression of Nicastrin. COX-2 decreases its expression when nimesulide is used. Conclusions: Our results suggest that C6 cell line is useful to analyze the effect of pro-inflammatory molecules on tau phosphorylation and APP expression in vitro . The beneficial effect on the reduction of tau hyperphosphorylation shown by citalopram, nimesulide and resveratrol should be taken with caution due to the limitations of the present study and further research on these compounds is needed to determine their therapeutic use in neurodegenerative diseases such as Alzheimer’s disease. Amaç: Alzheimer hastalığı karmaşıktır ve birkaç protein içerir. En çok etkilenenler, u-sekretaz (BACE1) ve γ-sekretaz (Nicastrin) enzimleri tarafından parçalandığında amiloid peptidi veren Tau proteini ve amiloid öncü proteinidir (APP). Bu süreçler esas olarak nöronlarda gerçekleşmesine rağmen, glia hücreleri de bu süreçlere katkıda bulunduğundan, bunlardan ayrı değildir. Amaç: Bu çalışmanın amacı, LPS’ye maruz kaldığında nimesulid, resveratrol ve sitalopramın C6 (glioma) hücreleri üzerindeki etkisini değerlendirmektir. Gereç ve Yöntem: APP, BACE1, COX-2, Nicastrin ve Tau-p proteinlerinin ekspresyon seviyeleri, LPS’nin etkisi ile C6 hücrelerinde Western-blot ve ELISA ve sitalopram, nimesulid ve resveratrol ilaçları ile değerlendirildi. Bulgular: Bu hücre modelinde LPS’nin Tau’yu hiperfosforilat edebildiği ve ilaçların hiperfosforilasyonu azalttığı bulundu. Ayrıca ilaçların APP ekspresyonunu arttırdığını, BACE1’i azalttığını ve Nicastrin ekspresyonunu teşvik ettiğini bulduk. Nimesulid kullanıldığında COX-2 ekspresyonunu azaltır. Sonuçlar: Sonuçlarımız, pro-enflamatuar moleküllerin tau fosforilasyonu ve in vitro APP ekspresyonu üzerindeki etkisini analiz etmek için C6 hücre hattının yararlı olduğunu göstermektedir. Sitalopram, nimesulid ve resveratrol tarafından gösterilen tau hiperfosforilasyonunun azaltılması üzerindeki yararlı etki, mevcut çalışmanın sınırlamaları nedeniyle dikkatle alınmalı ve bu bileşikler üzerinde, Alzheimer hastalığı gibi nörodejeneratif hastalıklarda terapötik kullanımlarının belirlenmesi için daha fazla araştırmaya ihtiyaç vardır.

6 January 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
FRFausto Rojas-Durán
Fausto Rojas-Durán
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
LMLuis Roberto Tlapa Monge
Luis Roberto Tlapa Monge
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, and Huntington’s disease represent a major challenge in neuroscience due to their complex, multifactorial nature and the absence of curative treatments. These disorders share common molecular mechanisms, including oxidative stress, mitochondrial dysfunction, proteostasis collapse, calcium dyshomeostasis, chronic neuroinflammation, and the prion-like propagation of misfolded proteins. Together, these processes trigger a cascade of cellular damage that culminates in synaptic dysfunction and programmed neuronal death. This review integrates current evidence on the sequential stages of neurodegeneration, emphasizing the convergence of oxidative, inflammatory, and proteotoxic pathways that drive neuronal vulnerability. Moreover, it explores emerging therapeutic strategies aimed at restoring cellular homeostasis, such as Nrf2 activation, modulation of the unfolded protein response (UPR), enhancement of autophagy, immunotherapy against pathological proteins, and gene therapy approaches. The dynamic interplay among mitochondria, endoplasmic reticulum, and glial cells is highlighted as a central element in disease progression. Understanding these interconnected mechanisms provides a foundation for developing multi-targeted interventions capable of halting or delaying neuronal loss and improving clinical outcomes in neurodegenerative disorders. This work provides an integrative and introductory overview of the convergent mechanisms underlying neurodegeneration rather than an exhaustive mechanistic analysis.

5 March 2024 in Environmental Research
Verified
Journal Article
Closed access
Huemantzin Balan Ortiz-OliverosHuemantzin Balan Ortiz-Oliveros
Huemantzin Balan Ortiz-Oliveros
MMM.M. Mendoza-Guzmán
M.M. Mendoza-Guzmán
GZG. Zarazúa-Ortega
G. Zarazúa-Ortega
NLN. Lara-Almazán
N. Lara-Almazán
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
AGAbraham Gonzalez
Abraham Gonzalez

1 October 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MRM. Ropacki
M. Ropacki
ANA. Navarro
A. Navarro
TMTamara Maes
Tamara Maes
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
RBR. Bullock
R. Bullock
CBC. Buesa
C. Buesa

18 January 2019
Verified
Book Chapter
Closed access
PDF file
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
JJJoan Arturo Jácome-Delgado
Joan Arturo Jácome-Delgado
VRViviana Yarel Rosales-Morales
Viviana Yarel Rosales-Morales
NCNicandro Cruz-Ramírez
Nicandro Cruz-Ramírez
GAGonzalo Emiliano Aranda-Abreu
Gonzalo Emiliano Aranda-Abreu